April 10, 2017 10:00 AM EDT

Private equity groups bag Stada in $5.6B buyout; Jefferies sees deteriorating prospects for AstraZeneca

Shehla Shakoor

Managing Director

→ The generics business is continuing to consolidate. Bain and Cinzen have done a deal to acquire Germany’s Stada for $5.6 billion. The private …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Private equity groups bag Stada in $5.6B buyout; Jefferies sees deteriorating prospects for AstraZeneca

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Pri­vate eq­ui­ty groups bag Sta­da in $5.6B buy­out; Jef­feries sees de­te­ri­o­rat­ing prospects for As­traZeneca

Managing Director

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Private equity groups bag Stada in $5.6B buyout; Jefferies sees deteriorating prospects for AstraZeneca